论文部分内容阅读
目的:观察舒普深治疗老年慢阻肺继发感染的临床疗效及安全性。方法:治疗组20例给予舒普深2.0 g,静脉滴注,2次/d,疗程5~10 d;对照组20例给予左氧氟沙星0.2 g静脉滴注,2次/d,疗程7~14 d。结果:舒普深、左氧氟沙星的临床总有效率分别为90%和75%,两组比较差异无统计学意义;不良反应发生率舒普深组和左氧氟沙星组均为10%,两组间比较无统计学意义。但总疗程治疗组比对照组缩短。结论:舒普深治疗老年慢阻肺继发感染的疗效及安全性好,是一种抗菌谱广、抗菌作用强的耐酶抗生素。
Objective: To observe the clinical efficacy and safety of Shu Pu-shen in the treatment of secondary infection of chronic obstructive pulmonary disease (COPD) in the elderly. Methods: Twenty cases in the treatment group were given Shuguang 2.0 g intravenous drip twice a day for 5 to 10 days. In the control group, 20 cases were given 0.2 g levofloxacin intravenously twice a day for 7-14 days . Results: The total clinical effective rates of Shu Pu Shen and Levofloxacin were 90% and 75%, respectively. There was no significant difference between the two groups. The incidence of adverse reactions was 10% in Shu Pu Shen and Levofloxacin groups, with no significant difference between the two groups Statistical significance. However, the total course of treatment than the control group shortened. Conclusion: Shu Pu-deep treatment of elderly COPD secondary infection efficacy and safety is good, is a wide antibacterial spectrum, antibacterial strong enzyme-resistant antibiotics.